![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EISAI LOOKS TO EXTEND FOOTPRINT IN INDIA
EISAI LOOKS TO EXTEND FOOTPRINT IN INDIA
September 13, 2005
Japanese drug major Eisai is looking to expand its footprint in India. Poised to roll out its blockbuster dementia drug Aricep, the company is conducting global clinical trials on the drug in India. Soichi Matsuno, Deputy President and Representative Executive Officer and Managing Director with the company's Global Pharmaceutical Business, said India's product patent protection regime favoured the entry of multinational companies into India. Eisai looks to benefit from the info-tech and medicinal chemistry skills in the country, he added.
Sify (http://sify.com/finance/equity/fullstory.php?id=13938725)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct